Nutritional composition comprising indigestible oligosaccharides

Patent metadata

Field	Value
Publication number	US-9566291-B2
Application number	US-57418005-A
Country	US
Kind code	B2
Filing date	Aug 24, 2005
Priority date	Aug 24, 2004
Publication date	Feb 14, 2017
Grant date	Feb 14, 2017

Abstract

The present invention provides a method and composition for the treatment and/or prevention of respiratory tract infection and/or respiratory tract infection disease, said method comprising orally administering a composition to a mammal, said composition comprising a galactose containing indigestible oligosaccharide and at least 5 wt. % digestible galactose saccharide.

First claim

The invention claimed is:

1. A method for reducing the occurrence of respiratory tract infections in a human infant between 0 and 2 years of age suffering from respiratory tract infections, said method comprising orally administering to the infant an infant formula composition free of human milk comprising:
(a) 0.1 to 12 grams indigestible galacto-oligosaccharides per 100 gram dry weight of the composition; and
(b) at least 5 weight % based on total dry weight of the composition of a digestible galactose saccharide, said saccharide being selected from the group consisting of galactose and digestible galactose having at least two terminal saccharide units, wherein one terminal saccharide unit is glucose or galactose, and the other terminal saccharide is galactose or fucose,
wherein the infant formula composition does not comprise a probiotic.

2. The method according to claim 1 , wherein the respiratory tract infection is a respiratory syncytial virus infection, childhood bronchiolitis and/or pediatric pneumonia.

3. The method according to claim 1 , wherein the treatment is for childhood bronchiolitis, pediatric pneumonia, or both.

4. The method according to claim 1 , wherein the human infant was born preterm or suffers from bronchopulmonary dysplasia, congenital heart disease, congenital or acquired immune deficiency syndrome, cystic fibrosis, chronic obstructive pulmonary disease, or diabetes.

5. The method according to claim 1 , wherein the galactose-oligosaccharides are transgalactooligosaccharides with a degree of polymerisation between 2 and 10.

6. The method according to claim 1 , wherein the composition further comprises a second indigestible oligosaccharide selected from the group consisting of fructooligosaccharides, hydrolysed inulin, and inulin.

7. The method according to claim 1 , wherein the composition further comprises a fat, carbohydrate, protein, or combinations thereof.

8. The method according to claim 7 , wherein the fat is a long chain polyunsaturated fatty acid selected from the group consisting of eicosapentaenoic acid, docosahexaenoic acid, and arachidonic acid.

9. The method according to claim 7 , wherein the fat, carbohydrate, or protein is of plant, non-human animal, bacterial, or synthetic origin.

10. The method according to claim 7 , comprising between 10 and 60 energy % fat, between 15 and 90 energy % carbohydrate, and between 5 and 50 energy % protein.

11. The method according to claim 1 , wherein the composition further comprises probiotic bacteria.

12. The method according to claim 11 , wherein the probiotic bacteria is Lactobacillus, Bifidobacterium, Lactococcus, Pediococcus, Enterococcus, Propionibacterium, Bacillus, Streptococcus , and combinations thereof.

13. The method according to claim 1 , wherein the composition further comprises acid oligosaccharides.

14. The method according to claim 1 , wherein the composition does not comprise an immunoglobulin having respiratory syncytial virus neutralizing activity.

15. The method according to claim 2 , wherein the composition comprises 0.1 to 12 grams of the transgalactooligosaccharides per 100 gram dry weight of the composition, and further comprises:
a. between 10 and 60 energy % lipid; between 5 and 50 energy % protein; and between 15 and 90 energy % carbohydrate;
b. between 40 and 60 weight % lactose based on total dry weight of the composition; and
c. at least one of eicosapentaenoic acid, docosahexaenoic acid, or arachidonic acid.

16. The method according to claim 1 , wherein the respiratory tract infection is an upper respiratory tract infection.

17. The method according to claim 1 , wherein the digestible galactose saccharide (b) is lactose.

18. A method for reducing the occurrence of respiratory tract infections in a human infant between 0 and 2 years of age suffering from respiratory tract infections, said method comprising orally administering to the infant an infant formula composition free of human milk and comprising:
(a) indigestible transgalactooligosaccharides with a degree of polymerisation between 2 and 10; and
(b) at least 5 weight % based on total dry weight of the composition of a digestible galactose saccharide, said saccharide being selected from the group consisting of galactose and digestible galactose having at least two terminal saccharide units, wherein one terminal saccharide unit is glucose or galactose, and the other terminal saccharide is galactose or fucose,
wherein the composition does not comprise a probiotic.

19. The method according to claim 18 , wherein the respiratory tract infection is a respiratory syncytial virus infection, childhood bronchiolitis and/or pediatric pneumonia.

20. The method according to claim 18 , wherein the composition further comprises a second indigestible oligosaccharide selected from the group consisting of fructooligosaccharides, hydrolysed inulin, and inulin.

21. The method according to claim 18 , wherein the composition does not comprise an immunoglobulin having respiratory syncytial virus neutralizing activity.

Assignees

• Boehm Günther
• M'Rabet Laura
• Stahl Bernd
• Garssen Johan
• Nutricia Nv

Inventors

• Boehm Günther
• M'Rabet Laura
• Stahl Bernd
• Garssen Johan

Classifications

• A61P31/14

  for RNA viruses · CPC title

• A61P31/18

  for HIV · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P31/12

  Antivirals · CPC title